Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 543

1.

Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.

Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R.

Virus Res. 2016 Feb 2;213:224-229. doi: 10.1016/j.virusres.2015.12.019. Epub 2015 Dec 29.

PMID:
26739425
2.

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R Jr, Glenn G, Smith G.

Vaccine. 2016 Apr 7;34(16):1927-35. doi: 10.1016/j.vaccine.2016.02.033. Epub 2016 Feb 24.

3.

Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease.

Luczkowiak J, Lasala F, Mora-Rillo M, Arribas JR, Delgado R.

J Infect Dis. 2018 Nov 22;218(suppl_5):S574-S581. doi: 10.1093/infdis/jiy302.

4.

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Lázaro-Frías A, Gómez-Medina S, Sánchez-Sampedro L, Ljungberg K, Ustav M, Liljeström P, Muñoz-Fontela C, Esteban M, García-Arriaza J.

J Virol. 2018 May 14;92(11). pii: e00363-18. doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.

5.

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.

DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A.

Vaccine. 2010 Dec 10;29(1):17-25. doi: 10.1016/j.vaccine.2010.10.024. Epub 2010 Oct 27.

6.

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.

Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G.

PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.

7.

An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.

Wu S, Kroeker A, Wong G, He S, Hou L, Audet J, Wei H, Zhang Z, Fernando L, Soule G, Tran K, Bi S, Zhu T, Yu X, Chen W, Qiu X.

J Infect Dis. 2016 Oct 15;214(suppl 3):S326-S332. Epub 2016 Aug 4. Erratum in: J Infect Dis. 2017 Jan 1;215(1):165.

8.

Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Schweneker M, Laimbacher AS, Zimmer G, Wagner S, Schraner EM, Wolferstätter M, Klingenberg M, Dirmeier U, Steigerwald R, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J.

J Virol. 2017 May 12;91(11). pii: e00343-17. doi: 10.1128/JVI.00343-17. Print 2017 Jun 1.

9.

Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.

Lingemann M, Liu X, Surman S, Liang B, Herbert R, Hackenberg AD, Buchholz UJ, Collins PL, Munir S.

J Virol. 2017 Apr 28;91(10). pii: e02469-16. doi: 10.1128/JVI.02469-16. Print 2017 May 15.

10.

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.

Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, Hellerstein MS, Guirakhoo F, Orlandi C, Flinko R, Lewis GK, Hanley PW, Feldmann H, Robinson HL, Marzi A.

Sci Rep. 2018 Jan 16;8(1):864. doi: 10.1038/s41598-017-19041-y.

11.

A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.

Chen T, Li D, Song Y, Yang X, Liu Q, Jin X, Zhou D, Huang Z.

Antiviral Res. 2017 Sep;145:54-59. doi: 10.1016/j.antiviral.2017.07.009. Epub 2017 Jul 18.

PMID:
28733113
12.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

13.

High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.

Konduru K, Shurtleff AC, Bavari S, Kaplan G.

J Virol Methods. 2018 Apr;254:1-7. doi: 10.1016/j.jviromet.2018.01.003. Epub 2018 Jan 31.

14.

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW.

Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

15.

Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus.

Krähling V, Becker D, Rohde C, Eickmann M, Eroğlu Y, Herwig A, Kerber R, Kowalski K, Vergara-Alert J, Becker S; European Mobile Laboratory consortium.

Med Microbiol Immunol. 2016 Apr;205(2):173-83. doi: 10.1007/s00430-015-0438-6. Epub 2015 Oct 16.

PMID:
26475282
16.

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.

Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM.

Science. 2016 Mar 4;351(6277):1078-83. doi: 10.1126/science.aad5788. Epub 2016 Feb 18.

17.

Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.

Vu H, Shulenin S, Grolla A, Audet J, He S, Kobinger G, Unfer RC, Warfield KL, Aman MJ, Holtsberg FW.

Antiviral Res. 2016 Feb;126:55-61. doi: 10.1016/j.antiviral.2015.11.012. Epub 2015 Dec 8.

18.

Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.

Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M.

J Clin Microbiol. 2016 Dec 28;55(1):165-176. doi: 10.1128/JCM.01979-16. Print 2017 Jan.

19.

Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus.

Macneil A, Reed Z, Rollin PE.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1175. doi: 10.1371/journal.pntd.0001175. Epub 2011 Jun 7.

20.

Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.

Rimoin AW, Lu K, Bramble MS, Steffen I, Doshi RH, Hoff NA, Mukadi P, Nicholson BP, Alfonso VH, Olinger G, Sinai C, Yamamoto LK, Ramirez CM, Okitolonda Wemakoy E, Kebela Illunga B, Pettitt J, Logue J, Bennett RS, Jahrling P, Heymann DL, Piot P, Muyembe-Tamfum JJ, Hensley LE, Simmons G.

J Infect Dis. 2018 Jan 4;217(2):223-231. doi: 10.1093/infdis/jix584.

Supplemental Content

Support Center